Archives — Current Month (12)
Canada-based biotech company signs major deal with Chinese partner to advance groundbreaking technology in the skin and tendon rejuvenation space.
This company's findings to date for its topical therapy candidate have encouraging implications for an orphan indication.
This "patient-care solution" is designed to help retailers make product recommendations.
Testing conducted as part of this Canadian company's research and development work on Parkinson's disease therapeutics has identified new potential antibody candidates.
A LifeSci Capital report presented a handful of key points about the firm.
An H.C. Wainwright & Co. report covered the greenlighting of two therapeutics developed by this firm, whose stock, according to the analyst, has more than fivebagger return potential.
Texas Heart Takes to the CoreoGraft (10/10/2018)
Daniel Carlson of Tailwinds Research profiles Hancock Jaffe Laboratories, which is partnering with the Texas Heart Institute to further develop an innovative graft designed for use in coronary bypass surgery.
This Utah-based company rolled out an online campaign that highlights its strategic repositioning.
A new, once-monthly injectable treatment for schizophrenia uses patents of a small-cap, U.S.-based pharmaceutical firm.
An H.C. Wainwright & Co. report reviewed this company's Q4/18 earnings and opportunities for increasing it.
A Ladenburg Thalmann report relayed how this Massachusetts company participated at the Transcatheter Cardiovascular Therapeutics annual meeting through a live transmission—the first ever—of a remote interventional procedure using the CorPath GRX system.
As the worldwide movement to ban antibiotics as a growth promoter in animal feed gains traction, technical analyst Clive Maund has called an "immediate strong buy" on a company that has developed an alternative.